TY - JOUR
T1 - A novel rat lipoxin A 4 receptor that is conserved in structure and function
AU - Chiang, Nan
AU - Takano, Tomoko
AU - Arita, Makoto
AU - Watanabe, Shiro
AU - Serhan, Charles N.
PY - 2003/5
Y1 - 2003/5
N2 - 1. Lipoxin (LX) A 4 and aspirin-triggered-LX (ATL) are endogenous lipid-derived mediators that regulate leukocyte trafficking via specific LXA 4 receptors (ALX), and are involved in endogenous anti-inflammation and resolution. Both LXA 4 and ATL are produced by rat tissues in vitro as well as in vivo. In rats, LXA 4 and ATL exhibit potent physiological and pathophysiological roles. Thus, we set out to determine whether ALX is expressed in rat tissues and its potential role in modulating leukocyte trafficking with LXA 4 and ATL. 2. In rats, a stable analog of ATL, when given intravenously with two consecutive doses at approximately 60 μg kg -1 each injection, significantly inhibited neutrophil infiltration (∼43%) and protein extravasation (∼42%) in a casein-induced peritonitis. 3. The rat orthologue of ALX was cloned from peripheral blood leukocytes encoding a putative G protein-coupled receptor (GPCR). It gave ∼74 and ∼84% homology, respectively to the deduced amino-acid sequences of the human and mouse ALX. 4. Tissue distribution analysis by RNase protection revealed that this rat receptor is expressed in tissues/cells, where LXA 4 displays physiological and pathophysiological roles, namely, lung, kidney and leukocytes. 5. The rat orthologue of ALX gave specific radioligand binding with [ 3H]LXA 4 and [ 125-Tyr]-annexin 1-derived peptide with apparent K d values of 5 and 820 nM, respectively, that are at levels comparable to those of the human ALX. 6. Activation of rat ALX inhibited tumor necrosis factor alpha-mediated nuclear factor kappaB activity in a ligand-dependent manner utilizing a luciferase reporter gene system. 7. Together, these results are the first demonstration of a rat ALX that is conserved in both structure and function suggesting that ALX plays key roles in regulating effector immune responses from murine to human species.
AB - 1. Lipoxin (LX) A 4 and aspirin-triggered-LX (ATL) are endogenous lipid-derived mediators that regulate leukocyte trafficking via specific LXA 4 receptors (ALX), and are involved in endogenous anti-inflammation and resolution. Both LXA 4 and ATL are produced by rat tissues in vitro as well as in vivo. In rats, LXA 4 and ATL exhibit potent physiological and pathophysiological roles. Thus, we set out to determine whether ALX is expressed in rat tissues and its potential role in modulating leukocyte trafficking with LXA 4 and ATL. 2. In rats, a stable analog of ATL, when given intravenously with two consecutive doses at approximately 60 μg kg -1 each injection, significantly inhibited neutrophil infiltration (∼43%) and protein extravasation (∼42%) in a casein-induced peritonitis. 3. The rat orthologue of ALX was cloned from peripheral blood leukocytes encoding a putative G protein-coupled receptor (GPCR). It gave ∼74 and ∼84% homology, respectively to the deduced amino-acid sequences of the human and mouse ALX. 4. Tissue distribution analysis by RNase protection revealed that this rat receptor is expressed in tissues/cells, where LXA 4 displays physiological and pathophysiological roles, namely, lung, kidney and leukocytes. 5. The rat orthologue of ALX gave specific radioligand binding with [ 3H]LXA 4 and [ 125-Tyr]-annexin 1-derived peptide with apparent K d values of 5 and 820 nM, respectively, that are at levels comparable to those of the human ALX. 6. Activation of rat ALX inhibited tumor necrosis factor alpha-mediated nuclear factor kappaB activity in a ligand-dependent manner utilizing a luciferase reporter gene system. 7. Together, these results are the first demonstration of a rat ALX that is conserved in both structure and function suggesting that ALX plays key roles in regulating effector immune responses from murine to human species.
KW - ALX
KW - Annexin 1
KW - Aspirin-triggered lipoxin
KW - GPCR
KW - Inflammation
KW - Lipoxin
UR - http://www.scopus.com/inward/record.url?scp=0037716533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037716533&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0705220
DO - 10.1038/sj.bjp.0705220
M3 - Article
C2 - 12746227
AN - SCOPUS:0037716533
SN - 0007-1188
VL - 139
SP - 89
EP - 98
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 1
ER -